Thuy-My L.
- Country
- The Netherlands
- Department
- Allergology Dep.
Research Overview
- A three-year, multi-center, double-blind, extension study to evaluate the long-term safety and efficacy of ligelizumab in patients who completed ligelizumab’s Phase III studies in food allergy
- A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Safety of Epicutaneous Immunotherapy with DBV712 250 µg in 1-through 3-year-old Children with Peanut Allergy
Data & Insights
Has run more than one trial at 5 of 24 partner sites.
Specializations
Allergy Research Focus
This investigator specializes in food allergy management and immunotherapy treatments, with particular emphasis on innovative therapeutic approaches for various food allergies.
- Food Allergy Treatment Development
- Pediatric Allergy Care
- Immunotherapy Research
The investigator's work centers on evaluating novel therapeutic options for patients with food allergies, including specialized treatments for children between 4-7 years of age.
Specialized Therapeutic Areas
Key research interests include the development and assessment of desensitization protocols and long-term safety evaluations of emerging allergy treatments.
- Peanut Allergy Interventions
- Safety Assessment Protocols
- Treatment Tolerance Studies
The investigator focuses on evaluating the efficacy and safety of innovative immunotherapy approaches for food allergies.
Clinical Innovation
Research activities concentrate on novel immunotherapy applications and therapeutic monitoring in allergy treatment.
- Long-term Treatment Outcomes
- Simplified Treatment Protocols
- Patient Safety Monitoring
The investigator examines the long-term effectiveness and tolerability of new therapeutic agents in food allergy management.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.